In emerging fields of interventional cardiology, success tends to come only after halting progress. In coronary artery disease, angioplasty catheters cleared arteries but elastic recoil caused them to close again, requiring stents to prop them open. Then stents caused an immune reaction leading to restenosis. Drug-eluting stents came along to deal with the new problem. Today, revascularization procedures produce high rates of efficacy. Atrial fibrillation is following a similar path. Earlier versions of radiofrequency catheters overheated tissue, so the tips were irrigated with solution to slow the burn. Irrigation solved one problem but created another – interventionalists no longer could confirm ablation by temperature measurement at the tissue surface. So instead, sensors were developed to measure the force with which the ablation probe contacts tissue so to give physicians feedback about whether they’re creating a competent lesion.
Device Companies Follow New Map To Atrial Fibrillation
Three years ago, the FDA approved Johnson & Johnson’s ThermoCool, the first in a series of ablation catheters specifically designed to halt atrial fibrillation. Despite these advances, the long-term success rates of catheter ablation procedures remain low, opening the door for start-ups to devise new approaches.